Clinical Trials Logo

Congestive Heart Failure Chronic clinical trials

View clinical trials related to Congestive Heart Failure Chronic.

Filter by:
  • None
  • Page 1

NCT ID: NCT05885425 Not yet recruiting - Clinical trials for Congestive Heart Failure Chronic

Management of Telemedicine Monitoring of Patients With Chronic Heart Failure

Start date: September 1, 2023
Phase:
Study type: Observational

Objective: to evaluate the possibilities and effect of telemedicine monitoring and management of patients with CHF (compared to patients with CHF without intensive telemedicine monitoring) on quality of life, prognosis and the presence of complications and hospitalisations. Patients with a stable form of congestive heart failure will be gradually included in the study. Half of them will be defined by random selection to intervention group. Parameters, that can be measured at home will be periodically telemedical monitored. In according with at home monitored data, the own physician will be able to intervene with change of medical treatment in the case of non-physiological deviations in order to improve the health status as well as the prognosis of the patient with CHF.

NCT ID: NCT04515537 Recruiting - Clinical trials for Congestive Heart Failure Chronic

Cyanophyta Aphanizomenon Flos-aquae, and Adipose Stroma Vascular Fraction, in Heart Failure Patient

Start date: May 20, 2021
Phase:
Study type: Observational

This study is a prospective, randomized, controlled trial to assess the efficacy of transplantation of autologous stroma vauscultar fraction and/or AFA in 15 patients with ischemic heart failure

NCT ID: NCT03525379 Completed - Clinical trials for Congestive Heart Failure Chronic

Evaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart Failure

REV-HF
Start date: October 26, 2017
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled trial evaluating the effect of resveratrol on metabolic and skeletal muscle function. Patients will be randomized and allocated to either resveratrol or placebo, for 8 weeks with a 2-week run-in period before the intervention period (to ensure they are not on any nutritional supplement that contains resveratrol).